ASMB Strangle Strategy
ASMB (Assembly Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
ASMB (Assembly Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $504.1M, a beta of 1.09 versus the broader market, a 52-week range of 12.19-39.71, average daily share volume of 109K, a public-listing history dating back to 2010, approximately 73 full-time employees. These structural characteristics shape how ASMB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.09 places ASMB roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on ASMB?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ASMB snapshot
As of May 15, 2026, spot at $28.84, ATM IV 73.20%, IV rank 14.87%, expected move 20.99%. The strangle on ASMB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ASMB specifically: ASMB IV at 73.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ASMB strangle, with a market-implied 1-standard-deviation move of approximately 20.99% (roughly $6.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ASMB expiries trade a higher absolute premium for lower per-day decay. Position sizing on ASMB should anchor to the underlying notional of $28.84 per share and to the trader's directional view on ASMB stock.
ASMB strangle setup
The ASMB strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ASMB near $28.84, the first option leg uses a $30.28 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ASMB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ASMB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $30.28 | N/A |
| Buy 1 | Put | $27.40 | N/A |
ASMB strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ASMB strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ASMB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ASMB
Strangles on ASMB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ASMB chain.
ASMB thesis for this strangle
The market-implied 1-standard-deviation range for ASMB extends from approximately $22.79 on the downside to $34.89 on the upside. A ASMB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ASMB IV rank near 14.87% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ASMB at 73.20%. As a Healthcare name, ASMB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ASMB-specific events.
ASMB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ASMB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ASMB alongside the broader basket even when ASMB-specific fundamentals are unchanged. Always rebuild the position from current ASMB chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ASMB?
- A strangle on ASMB is the strangle strategy applied to ASMB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ASMB stock trading near $28.84, the strikes shown on this page are snapped to the nearest listed ASMB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ASMB strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ASMB strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 73.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ASMB strangle?
- The breakeven for the ASMB strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ASMB market-implied 1-standard-deviation expected move is approximately 20.99%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ASMB?
- Strangles on ASMB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ASMB chain.
- How does current ASMB implied volatility affect this strangle?
- ASMB ATM IV is at 73.20% with IV rank near 14.87%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.